The McDonnell Genome Institute, WashU Medicine

As we kick off 2025, we’re excited to share our 2024 Fee-for-Service Multi-omics Industry Report, based on a survey MGI conducted with researchers in biotech, pharma, and academia. The report highlights key trends and insights on where the field is headed, including the growing demand for integrated multi-omics data, the role of advanced computational tools, and the rise of new technologies like high-plex proteomics and spatial omics. This snapshot offers a glimpse into the future of multi-omics research and the challenges and opportunities that lie ahead. Check out the full report for more on the evolving landscape of multi-omics and its impact on precision medicine. #precisionmedicine #proteomics #bioinformatics Washington University School of Medicine in St. Louis Broad Institute of MIT and Harvard https://lnkd.in/eqpB5hMr

Last fall, we hosted the Proteomics: Biomarker and Disease Research Symposium at the new Jeffrey T. Fort Neuroscience Research Building at Washington University School of Medicine in St. Louis, featuring a lineup of exceptional speakers, including Dr. Josef Coresh, the Terry and Mel Karmazin Professor of Population Health and Medicine at NYU Grossman School of Medicine. Dr. Coresh’s talk delved into the evolution of proteomics platforms, such as SomaScan (SomaLogic) and Olink, and their application in understanding cardiovascular, renal, and neurodegenerative diseases. He shared insights into the challenges of measuring thousands of plasma proteins with precision and how proteomics is transforming human health. With over 350,000 citations to his name, Dr. Coresh is one of the most highly cited researchers in the field of high-plex proteomics, and we were thrilled to feature him. Watch his full talk below. #proteomics #neuro #precisionmedicine

Happy New Year!

As 2024 comes to a close, we reflect on a year of innovation and discovery at the McDonnell Genome Institute. One of the most exciting highlights has been the recognition of spatial proteomics as Nature Magazine's Method of the Year. This groundbreaking technology is reshaping how we understand cellular biology and disease mechanisms. At MGI, our Mass Spectrometry Technology Access Center designated as a Thermo Fisher Scientific Center of Excellence and a Bruker Center of Collaboration, plays a critical role in advancing research in proteomics, metabolomics, and spatially resolved omics. These partnerships reflect our commitment to providing researchers with access to cutting-edge technologies and expertise. We’re excited to share a new video showcasing our incredible MTAC lab space. Take a look inside to see the facilities and tools that enable breakthroughs in multi-omics research. #proteomics #precisionmedicine #massspec

We’ve brought Scott Huegerich from Aligned Media and their crew back into the MGI labs to highlight the people and technologies behind our work. From genomics and gene engineering to high-plex proteomics and functional imaging, these capabilities are helping researchers answer complex scientific questions. Keep an eye on our page for the footage soon. Special thanks to William Buchser, Colin Kremitzki, Jason Waligorski, Emanuel Gerbi, and several others who participated!

The Functional Imaging and Variant Evaluation (FIVE) team at MGI has developed a Single Neuron Identification model to identify and classify single neurons in stem cell-derived cultures. Trained on the SNIM20 dataset—a collection of high-resolution images from iPSC-derived neuronal cultures—the model allows researchers to pinpoint and analyze individual neurons with precision. Why does this matter? Accurate identification of single neurons is critical for understanding how genetic variants impact neuronal behavior, particularly in neurodegenerative diseases like ALS and Alzheimer’s. This tool provides a scalable solution to link genetic changes to phenotypes, explore disease mechanisms, and identify new therapeutic targets. The technology, along with details about its development, is available here: https://lnkd.in/gVtFrDUp Washington University School of Medicine in St. Louis, Invitrogen, MilliporeSigma, Hugging Face, R&D Systems, Lonza, Thermo Fisher Scientific, Corning Pharmaceutical Technologies, STEMCELL Technologies

When it comes to cancer care and research, we are on the precipice of incredible discovery and critical advancement of human health. With more than 75,000 patients served annually, 700 therapeutic clinical trials per year and 600 WashU Medicine physicians and scientists at the helm, WashU Medicine, in collaboration with Siteman Cancer Center and Barnes-Jewish hospital, is a national leader in cancer care. I hope you’ll take some time to read our latest issue of Outlook Magazine, where we dive deep into the incredible work, people and stories of cancer happening here at WashU Medicine. https://outlook.washu.edu

Biomarker discovery relies on robust methodologies to uncover, verify, and validate molecular signatures with clinical potential. Mass spectrometry-based proteomics is a powerful tool in this process, offering unparalleled precision and versatility across key phases of discovery. In the Discovery Phase, unbiased LC-MS/MS workflows enable hypothesis generation and comprehensive protein identification. The Verification Phase applies targeted approaches like SRM and PRM to refine the focus to a smaller set of key proteins. Finally, the Validation Phase ensures these biomarkers demonstrate clinical utility through precise quantification in larger, diverse cohorts. The flexibility and precision of mass spectrometry make it an indispensable approach for understanding complex biological systems and advancing translational research. At the McDonnell Genome Institute, we offer both mass spectrometry and high-plex proteomics services to empower researchers at every stage of biomarker discovery, driving meaningful progress toward clinical application. For more information on our mass spec services, please visit: #massspec #proteomics #precisionmedicine Biomarkers & Biomarker Studies BPOF-APGCS - 2nd Biomarkers and Precision Oncology Forum & 11th Asia Pacific Gastroenterology Cancer Biomarker Analysis Services BiomarkerBase™ Learning Page

Mass spectrometry provides researchers with unparalleled flexibility to analyze a diverse range of biological samples, from fluids like blood and CSF to tissues, cells, and organelles. Its ability to detect proteoforms, including isoforms and post-translational modifications, makes it a critical tool for understanding complex biological systems. Analyze proteins across species with mass spectrometry-based proteomics. Detect proteoforms with precision, including isoforms and post-translational modifications. Work with diverse sample types, such as biological fluids (blood, urine, CSF, BALF, saliva, tears), tissues, cells, and organelles (mitochondria, vesicles, ECM). Handle extreme dynamic ranges of proteins in complex matrices like blood. MGI offers advanced mass spectrometry capabilities to complement its multi-omic services, empowering researchers to tackle complex biological questions with precision. #MassSpec #Proteomics #Multiomics

At the McDonnell Genome Institute, we have developed a method for reliably generating multi-kilobase knock-in (KI) mice and cell lines using three rAAV donors and CRISPR/Cas9 via consecutive homology-directed repair. This approach allowed us to produce over 120 KI mice, addressing the challenges of large genomic insertions. To analyze the post-edit genome, we combined target capture with long-read sequencing, creating a high-throughput, multiplexable method to detect on-target insertions as well as undesired editing outcomes. Together, these tools provide a robust framework for improving the efficiency and accuracy of large KI model development. This new technique could help accelerate drug development by enabling researchers to better mimic human diseases, validate drug targets more efficiently, and improve the predictive accuracy of preclinical models. For more details, read the preprint: https://lnkd.in/gGcQ57fy